pDONR P2R-P3-EGFP
(Plasmid
#48349)
-
PurposeContributes the coding sequence for EGFP as the 3’-module during MultiSite Gateway-cloning of chimeric cDNAs encoding three-part fusion proteins.
-
Depositing Labs
-
Sequence Information
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 48349 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backbonepDONRP2R-P3
-
Backbone manufacturerLife Technologies/Invitrogen
- Backbone size w/o insert (bp) 2651
- Total vector size (bp) 3359
-
Vector typeGateway entry vector
Growth in Bacteria
-
Bacterial Resistance(s)Kanamycin, 50 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)Top10
-
Copy numberHigh Copy
Gene/Insert
-
Gene/Insert nameEGFP
-
SpeciesSynthetic; Aequorea victoria
-
Insert Size (bp)708
-
MutationAminoacid 40 is valine in our sequence, while it is phenylalanine in other EGFP sequences. This does not seem to affect fluorescence. Contains a stop codon.
- Promoter none
Cloning Information
- Cloning method Gateway Cloning
- 5′ sequencing primer M13 forward (-20)
- 3′ sequencing primer M13 reverse (Common Sequencing Primers)
Resource Information
-
A portion of this plasmid was derived from a plasmid made byClontech
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
pDONR P2R-P3-EGFP was a gift from Anna Planas & Tomas Santalucia (Addgene plasmid # 48349 ; http://n2t.net/addgene:48349 ; RRID:Addgene_48349) -
For your References section:
A plasmid toolkit for cloning chimeric cDNAs encoding customized fusion proteins into any Gateway destination expression vector. Buj R, Iglesias N, Planas AM, Santalucia T. BMC Mol Biol. 2013 Aug 20;14(1):18. doi: 10.1186/1471-2199-14-18. 10.1186/1471-2199-14-18 PubMed 23957834